SAN Sanofi

Sanofi - AGM 30.04.2024 - Availability of Preparatory documents

Sanofi - AGM 30.04.2024 - Availability of Preparatory documents

COMBINED GENERAL MEETING OF APRIL 30, 2024

AVAILABILITY OF PREPARATORY DOCUMENTS

The Company’s shareholders are invited to attend the Combined General Meeting to be held on Thursday April 30, 2024 at 2:30 p.m. (CET) at the Palais des Congrès – Amphithéâtre Bleu – 2, place de la Porte Maillot – 75017 Paris.

The notice of meeting (avis de réunion), including the agenda and the draft resolutions as well as the terms and conditions for participating and voting in the meeting, was published on the website of the Bulletin des Annonces Légales ObligatoiresBALO” () on March 15, 2024, bulletin n°33.

The notice of meeting (avis de convocation) will be published on the website of the Bulletin des Annonces Légales ObligatoiresBALO” () on April 12, 2024.

The preparatory documents for this meeting will be made available to the shareholders in accordance with the applicable legal and regulatory provisions.

For registered shareholders, you will receive your notice of the General Meeting directly by post or by e-mail, depending on your choice. To request additional documents, you must complete the document request form on page 61 of the notice of meeting and return it to Uptevia, Assemblées Générales – 90-110 esplanade du Général de Gaulle – 92931 Paris La Défense CEDEX, no later than April 25, 2024.

For bearer shareholders, you should contact your financial intermediary.

In accordance with Article R. 22-10-23 of the French Commercial Code, the preparatory documents for this meeting are available on the Company’s website: .

We invite you to regularly consult the “Annual General Meetings” section of our website, which will be updated with any changes regarding the participation in the meeting.

* * *

Attachment



EN
08/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Press Release: Sanofi adds over €1 billion for biomanufacturing to €2....

Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty   Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty Paris, May 13, 2024. As the largest private contributor to the security and independence of France's health ecosystem, Sanofi today announces an investment of more than €1 billion to create new bioproduction capacity at its sites in Vitry-sur-Seine (Val de Marne), Le Trait (Seine-Maritime) a...

 PRESS RELEASE

Press Release: Sanofi and Novavax announce co-exclusive licensing agre...

Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines   Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Accelerates potential for development of a novel flu-COVID-19 combination product based on authorized vaccines with ...

 PRESS RELEASE

Communiqué de presse : Sanofi et Novavax concluent un accord de licenc...

Communiqué de presse : Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19 Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19 L’accord, qui combinera la puissance commerciale des deux entreprises, permettra aux patients de bénéficier à partir de 2025 d’un meilleur accès à un vaccin adjuvanté à base de protéines, non-ARNm, contre la COVID-19 Accélération du ...

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Sanofi - The Path to €120 (BUY, TP EUR120 [110], 7pgs)

This new analysis shows how Sanofi shares get to €120 (+c.30%) by end 2025. We have conducted a foundational analysis that investors can refer to over the next 18mths as Sanofi releases at least 15 P2 & P3 pipeline readouts. We show the upside potential from every single readout and show that just 4 drugs could add €18/share upon successful readouts. In addition to multiple readouts, the likely Consumer Health spin in Q4, the tolebrutinib overhang being resolved one way or another and a strong C...

 PRESS RELEASE

Press Release: Beyfortus real-world evidence published in The Lancet s...

Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the o...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch